|
1
|
Siegel R, Naishadham D and Jemal A: Cancer
statistics, 2012. CA Cancer J Clin. 62:10–29. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Dinney CP, McConkey DJ, Millikan RE, Wu X,
Bar-Eli M, Adam L, Kamat AM, Siefker-Radtke AO, Tuziak T, Sabichi
AL, et al: Focus on bladder cancer. Cancer Cell. 6:111–116. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Jebar AH, Hurst CD, Tomlinson DC, Johnston
C, Taylor CF and Knowles MA: FGFR3 and Ras gene mutations are
mutually exclusive genetic events in urothelial cell carcinoma.
Oncogene. 24:5218–5225. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
McConkey DJ, Lee S, Choi W, Tran M,
Majewski T, Lee S, Siefker-Radtke A, Dinney C and Czerniak B:
Molecular genetics of bladder cancer: emerging mechanisms of tumor
initiation and progression. Urol Oncol. 28:429–440. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Babjuk M, Oosterlinck W, Sylvester R,
Kaasinen E, Böhle A and Palou-Redorta J: European Association of
Urology (EAU): EAU guidelines on non-muscle-invasive urothelial
carcinoma of the bladder. Eur Urol. 54:303–314. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Lamm DL, Riggs DR, Traynelis CL and Nseyo
UO: Apparent failure of current intravesical chemotherapy
prophylaxis to influence the long-term course of superficial
transitional cell carcinoma of the bladder. J Urol. 153:1444–1450.
1995. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Bartel DP: MicroRNAs: genomics,
biogenesis, mechanism, and function. Cell. 116:281–297. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Bartel DP: MicroRNAs: target recognition
and regulatory functions. Cell. 136:215–233. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Esquela-Kerscher A and Slack FJ: Oncomirs
- microRNAs with a role in cancer. Nat Rev Cancer. 6:259–269. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Dyrskjøt L, Ostenfeld MS, Bramsen JB,
Silahtaroglu AN, Lamy P, Ramanathan R, Fristrup N, Jensen JL,
Andersen CL, Zieger K, et al: Genomic profiling of microRNAs in
bladder cancer: miR-129 is associated with poor outcome and
promotes cell death in vitro. Cancer Res. 69:4851–4860. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Rubin R and Baserga R: Insulin-like growth
factor-I receptor. Its role in cell proliferation, apoptosis, and
tumorigenicity. Lab Invest. 73:311–331. 1995.PubMed/NCBI
|
|
12
|
Macaulay VM: Insulin-like growth factors
and cancer. Br J Cancer. 65:311–320. 1992. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Hanahan D and Weinberg RA: The hallmarks
of cancer. Cell. 100:57–70. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Baserga R: Controlling IGF-receptor
function: a possible strategy for tumor therapy. Trends Biotechnol.
14:150–152. 1996. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Qian X, Yu J, Yin Y, He J, Wang L, Li Q,
Zhang LQ, Li CY, Shi ZM, Xu Q, et al: MicroRNA-143 inhibits tumor
growth and angiogenesis and sensitizes chemosensitivity to
oxaliplatin in colorectal cancers. Cell Cycle. 12:1385–1394. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Rochester MA, Patel N, Turney BW, Davies
DR, Roberts IS, Crew J, Protheroe A and Macaulay VM: The type 1
insulin-like growth factor receptor is over-expressed in bladder
cancer. BJU Int. 100:1396–1401. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Chen C, Ridzon DA, Broomer AJ, Zhou Z, Lee
DH, Nguyen JT, Barbisin M, Xu NL, Mahuvakar VR, Andersen MR, et al:
Real-time quantification of microRNAs by stem-loop RT-PCR. Nucleic
Acids Res. 33:e1792005. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Wang X: A PCR-based platform for microRNA
expression profiling studies. RNA. 15:716–723. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Jing Y, Liu LZ, Jiang Y, Zhu Y, Guo NL,
Barnett J, Rojanasakul Y, Agani F and Jiang BH: Cadmium increases
HIF-1 and VEGF expression through ROS, ERK, and AKT signaling
pathways and induces malignant transformation of human bronchial
epithelial cells. Toxicol Sci. 125:10–19. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
He J, Qian X, Carpenter R, Xu Q, Wang L,
Qi Y, Wang ZX, Liu LZ and Jiang BH: Repression of miR-143 mediates
Cr (VI)-induced tumor angiogenesis via IGF-IR/IRS1/ERK/IL-8
pathway. Toxicol Sci. 134:26–38. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Fang R, Xiao T, Fang Z, Sun Y, Li F, Gao
Y, Feng Y, Li L, Wang Y, Liu X, et al: MicroRNA-143 (miR-143)
regulates cancer glycolysis via targeting hexokinase 2 gene. J Biol
Chem. 287:23227–23235. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Gregersen LH, Jacobsen A, Frankel LB, Wen
J, Krogh A and Lund AH: MicroRNA-143 down-regulates Hexokinase 2 in
colon cancer cells. BMC Cancer. 12:2322012. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Kent OA, Fox-Talbot K and Halushka MK:
RREB1 repressed miR-143/145 modulates KRAS signaling through
downregulation of multiple targets. Oncogene. 32:2576–2585. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Metalli D, Lovat F, Tripodi F, Genua M, Xu
SQ, Spinelli M, Alberghina L, Vanoni M, Baffa R, Gomella LG, et al:
The insulin-like growth factor receptor I promotes motility and
invasion of bladder cancer cells through Akt- and mitogen-activated
protein kinase-dependent activation of paxillin. Am J Pathol.
176:2997–3006. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Sekar D, Islam VI Hairul,
Thirugnanasambantham K and Saravanan S: Relevance of miR-21 in HIV
and non-HIV-related lymphomas. Tumour Biol. 35:8387–8393. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Iida K, Fukushi J, Matsumoto Y, Oda Y,
Takahashi Y, Fujiwara T, Fujiwara-Okada Y, Hatano M, Nabashima A,
Kamura S and Iwamoto Y: miR-125b develops chemoresistance in Ewing
sarcoma/primitive neuroectodermal tumor. Cancer Cell Int.
13:212013. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Han Y, Chen J, Zhao X, Liang C, Wang Y,
Sun L, Jiang Z, Zhang Z, Yang R, Chen J, et al: MicroRNA expression
signatures of bladder cancer revealed by deep sequencing. PLoS One.
6:e182862011. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Noguchi S, Mori T, Hoshino Y, Maruo K,
Yamada N, Kitade Y, Naoe T and Akao Y: MicroRNA-143 functions as a
tumor suppressor in human bladder cancer T24 cells. Cancer Lett.
307:211–220. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Ak S, Tunca B, Tezcan G, Cecener G, Egeli
U, Yilmazlar T, Ozturk E and Yerci O: MicroRNA expression patterns
of tumors in early-onset colorectal cancer patients. J Surg Res.
191:113–122. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Ng EK, Li R, Shin VY, Siu JM, Ma ES and
Kwong A: MicroRNA-143 is downregulated in breast cancer and
regulates DNA methyltransferases 3A in breast cancer cells. Tumour
Biol. 35:2591–2598. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Hart LS, Dolloff NG, Dicker DT, Koumenis
C, Christensen JG, Grimberg A and El-Deiry WS: Human colon cancer
stem cells are enriched by insulin-like growth factor-1 and are
sensitive to figitumumab. Cell Cycle. 10:2331–2338. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Zhao D, Bakirtzi K, Zhan Y, Zeng H, Koon
HW and Pothoulakis C: Insulin-like growth factor-1 receptor
transactivation modulates the inflammatory and proliferative
responses of neurotensin in human colonic epithelial cells. J Biol
Chem. 286:6092–6099. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Zhu Z, Xu T, Wang L, Wang X, Zhong S, Xu C
and Shen Z: MicroRNA-145 directly targets the insulin-like growth
factor receptor I in human bladder cancer cells. FEBS Lett.
588:3180–3185. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Berns K, Horlings HM, Hennessy BT,
Madiredjo M, Hijmans EM, Beelen K, Linn SC, Gonzalez-Angulo AM,
Stemke-Hale K, Hauptmann M, et al: A functional genetic approach
identifies the PI3K pathway as a major determinant of trastuzumab
resistance in breast cancer. Cancer Cell. 12:395–402. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Park BH and Davidson NE: PI3 kinase
activation and response to trastuzumab therapy: what's neu with
herceptin resistance? Cancer Cell. 12:297–299. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Vivanco I and Sawyers CL: The
phosphatidylinositol 3-kinase AKT pathway in human cancer. Nat Rev
Cancer. 2:489–501. 2002. View
Article : Google Scholar : PubMed/NCBI
|
|
37
|
Hennessy BT, Smith DL, Ram PT, Lu Y and
Mills GB: Exploiting the PI3K/AKT pathway for cancer drug
discovery. Nat Rev Drug Discov. 4:988–1004. 2005. View Article : Google Scholar : PubMed/NCBI
|
